Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.

Hims & Hers Health will have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to bar the game’s host, Fox, from broadcasting it. Why? Experts and advocates in the health care space are saying that the 60-second spot — which deems obesity “America’s deadliest epidemic,

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived deal for consumers.

The tele-health company Hims & Hers Health is facing scrutiny after critics say its Super Bowl ad promotes weight loss drugs that are not FDA-approved.